Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1276889

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1276889

MEA Non-Hodgkin Lymphoma Diagnostics Market - Industry Trends and Forecast to 2030

PUBLISHED:
PAGES: 325 Pages
DELIVERY TIME: Inquiry
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

Description

Table of Contents

List of Tables

The Middle East and Africa non-Hodgkin lymphoma diagnostics market is projected to register a substantial CAGR of 6.3% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Middle East and Africa Non-Hodgkin Lymphoma Diagnostics Market, By Test Type (Imaging, Biopsy, Immunohistochemistry, Biomarker Test, Genetic Test, Cytogenetics, Lumbar Puncture (Spinal Tap), Blood Test and Cytochemistry), Cancer Stage (Stage IV, Stage III, Stage II, Stage I, and Stage 0), Tumor Type (Aggressive Lymphomas and Indolent Lymphomas), Product (Instrument Based Products, Platform Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of Middle East and Africa non-Hodgkin lymphoma diagnostics market are:

Increased growth in the prevalence of non-Hodgkin lymphoma

Advancement in artificial intelligence in the diagnosis of non-Hodgkin lymphoma

Market Players:

Some of the major players operating in the Middle East and Africa non-Hodgkin lymphoma diagnostics market are:

CANON MEDICAL SYSTEMS CORPORATION

Koninklijke Philips N.V.

Siemens Healthcare GmbH

Danaher.

Bio-Rad Laboratories, Inc.

General Electric Company

Sysmex Corporation

Grail

F. Hoffmann-La Roche

Neusoft Corporation

Agilent Technologies, Inc.

NeoGenomics Laboratories

Hologic, Inc

Integrated DNA Technologies, Inc.

CENTOGENE N.V.

Merit Medical Systems

Invitae Corporation

PerkinElmer Inc.

QIAGEN

GeneDx, LLC

Show more

TABLE OF CONTENTS

1 INTRODUCTION 83

  • 1.1 OBJECTIVES OF THE STUDY 83
  • 1.2 MARKET DEFINITION 83
  • 1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET 83
  • 1.4 LIMITATIONS 85
  • 1.5 MARKETS COVERED 86

2 MARKET SEGMENTATION 89

  • 2.1 MARKETS COVERED 89
  • 2.2 GEOGRAPHICAL SCOPE 90
  • 2.3 YEARS CONSIDERED FOR THE STUDY 91
  • 2.4 CURRENCY AND PRICING 91
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 92
  • 2.6 MULTIVARIATE MODELLING 95
  • 2.7 PRODUCT TYPE LIFELINE CURVE 95
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 96
  • 2.9 DBMR MARKET POSITION GRID 97
  • 2.10 MARKET APPLICATION COVERAGE GRID 98
  • 2.11 VENDOR SHARE ANALYSIS 99
  • 2.12 SECONDARY SOURCES 100
  • 2.13 ASSUMPTIONS 100

3 EXECUTIVE SUMMARY 101

4 PREMIUM INSIGHTS 104

  • 4.1 PESTEL ANALYSIS 105
  • 4.2 PORTER'S 5 FORCES 106

5 INDUSTRY INSIGHTS 107

6 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, REGULATIONS 108

7 MARKET OVERVIEW 110

  • 7.1 DRIVERS 112
    • 7.1.1 INCREASED GROWTH IN PREVALENCE OF NON-HODGKIN LYMPHOMA 112
    • 7.1.2 INCREASE IN AWARENESS REGARDING NON-HODGKIN LYMPHOMA 112
    • 7.1.3 ADVANCEMENT IN ARTIFICIAL INTELLIGENCE IN DIAGNOSIS OF NON-HODGKIN LYMPHOMA 112
    • 7.1.4 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UP 113
  • 7.2 RESTRAINTS 113
    • 7.2.1 LACK OF AVAILABILITY OF TRAINED AND SKILLED MEDICAL PROFESSIONALS 113
    • 7.2.2 STRINGENT REGULATIONS AND GUIDELINES FOR DIFFERENT TREATMENTS AND DIAGNOSIS 114
  • 7.3 OPPORTUNITIES 115
    • 7.3.1 TECHNICAL ADVANCEMENTS IN CANCER DIAGNOSIS 115
    • 7.3.2 INCREASING HEALTHCARE EXPENDITURE IN CANCER R&D 115
    • 7.3.3 GROWING INITIATIVES BY GOVERNMENT AND KEY PLAYERS 115
  • 7.4 CHALLENGES 116
    • 7.4.1 LACK OF EARLY DIAGNOSTIC AWARENESS AMONG PEOPLE 116
    • 7.4.2 HIGH DIAGNOSTIC COST AND FEAR OF TREATMENT 116
    • 7.4.3 COMMON MISDIAGNOSIS OF NON-HODGKIN LYMPHOMA (NHL) 117

8 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TEST TYPE 118

  • 8.1 OVERVIEW 119
  • 8.2 IMAGING 122
    • 8.2.1 COMPUTED TOMOGRAPHY (CT) 123
    • 8.2.2 CHEST X-RAY 123
    • 8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 123
    • 8.2.4 ULTRASOUND 123
    • 8.2.5 POSITRON EMISSION TOMOGRAPHY (PET) 123
  • 8.3 BIOPSY 123
    • 8.3.1 EXCISIONAL OR INCISIONAL BIOPSY 124
    • 8.3.2 CORE NEEDLE BIOPSY 124
  • 8.4 IMMUNOHISTOCHEMISTRY 124
  • 8.5 BIOMARKER TEST 125
    • 8.5.1 BETA 2-M 126
    • 8.5.2 LDH 126
    • 8.5.3 CA-125 126
    • 8.5.4 TP53 126
    • 8.5.5 NPM1 127
    • 8.5.6 OTHERS 127
  • 8.6 GENETIC TEST 127
  • 8.7 CYTOGENETICS 127
  • 8.8 LUMBAR PUNCTURE (SPINAL TAP) 128
  • 8.9 BLOOD TEST 129
  • 8.10 CYTOCHEMISTRY 129
  • 8.11 OTHERS 130

9 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TUMOR TYPE 131

  • 9.1 OVERVIEW 132
  • 9.2 AGGRESSIVE LYMPHOMAS 134
    • 9.2.1 DIFFUSE LARGE B CELL LYMPHOMA 135
      • 9.2.1.1 INSTRUMENT BASED PRODUCTS 136
      • 9.2.1.2 PLATFORM BASED PRODUCTS 136
      • 9.2.1.3 KITS AND REAGENTS 136
      • 9.2.1.4 OTHER CONSUMABLES 136
    • 9.2.2 ANAPLASTIC LARGE-CELL LYMPHOMA 136
      • 9.2.2.1 INSTRUMENT BASED PRODUCTS 137
      • 9.2.2.2 PLATFORM BASED PRODUCTS 137
      • 9.2.2.3 KITS AND REAGENTS 137
      • 9.2.2.4 OTHER CONSUMABLES 137
    • 9.2.3 MANTLE CELL LYMPHOMA 137
      • 9.2.3.1 INSTRUMENT BASED PRODUCTS 138
      • 9.2.3.2 PLATFORM BASED PRODUCTS 138
      • 9.2.3.3 KITS AND REAGENTS 138
      • 9.2.3.4 OTHER CONSUMABLES 138
    • 9.2.4 PERIPHERAL T-CELL LYMPHOMA 138
      • 9.2.4.1 INSTRUMENT BASED PRODUCTS 139
      • 9.2.4.2 PLATFORM BASED PRODUCTS 139
      • 9.2.4.3 KITS AND REAGENTS 139
      • 9.2.4.4 OTHER CONSUMABLES 139
    • 9.2.5 LYMPHOBLASTIC LYMPHOMA 139
      • 9.2.5.1 INSTRUMENT BASED PRODUCTS 140
      • 9.2.5.2 PLATFORM BASED PRODUCTS 140
      • 9.2.5.3 KITS AND REAGENTS 140
      • 9.2.5.4 OTHER CONSUMABLES 140
    • 9.2.6 BURKITT LYMPHOMA 140
      • 9.2.6.1 INSTRUMENT BASED PRODUCTS 141
      • 9.2.6.2 PLATFORM BASED PRODUCTS 141
      • 9.2.6.3 KITS AND REAGENTS 141
      • 9.2.6.4 OTHER CONSUMABLES 141
  • 9.3 INDOLENT LYMPHOMAS 141
    • 9.3.1 FOLLICULAR LYMPHOMA 142
      • 9.3.1.1 INSTRUMENT BASED PRODUCTS 143
      • 9.3.1.2 PLATFORM BASED PRODUCTS 143
      • 9.3.1.3 KITS AND REAGENTS 143
      • 9.3.1.4 OTHER CONSUMABLES 143
    • 9.3.2 CUTANEOUS T-CELL LYMPHOMA 143
      • 9.3.2.1 INSTRUMENT BASED PRODUCTS 144
      • 9.3.2.2 PLATFORM BASED PRODUCTS 144
      • 9.3.2.3 KITS AND REAGENTS 144
      • 9.3.2.4 OTHER CONSUMABLES 144
    • 9.3.3 MARGINAL ZONE B CELL LYMPHOMA 144
      • 9.3.3.1 INSTRUMENT BASED PRODUCTS 145
      • 9.3.3.2 PLATFORM BASED PRODUCTS 145
      • 9.3.3.3 KITS AND REAGENTS 145
      • 9.3.3.4 OTHER CONSUMABLES 145
    • 9.3.4 LYMPHOPLASMACYTIC LYMPHOMA 145
      • 9.3.4.1 INSTRUMENT BASED PRODUCTS 146
      • 9.3.4.2 PLATFORM BASED PRODUCTS 146
      • 9.3.4.3 KITS AND REAGENTS 146
      • 9.3.4.4 OTHER CONSUMABLES 146
    • 9.3.5 SMALL-CELL LYMPHOCYTIC LYMPHOMA 146
      • 9.3.5.1 INSTRUMENT BASED PRODUCTS 147
      • 9.3.5.2 PLATFORM BASED PRODUCTS 147
      • 9.3.5.3 KITS AND REAGENTS 147
      • 9.3.5.4 OTHER CONSUMABLES 147

10 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY APPLICATION 148

  • 10.1 OVERVIEW 149
  • 10.2 SCREENING 151
    • 10.2.1 INSTRUMENT BASED PRODUCTS 152
    • 10.2.2 PLATFORM BASED PRODUCTS 152
    • 10.2.3 KITS AND REAGENTS 153
    • 10.2.4 OTHER CONSUMABLES 153
  • 10.3 DIAGNOSTIC AND PREDICTIVE 153
    • 10.3.1 INSTRUMENT BASED PRODUCTS 154
    • 10.3.2 PLATFORM BASED PRODUCTS 154
    • 10.3.3 KITS AND REAGENTS 154
    • 10.3.4 OTHER CONSUMABLES 154
  • 10.4 PROGNOSTIC 154
    • 10.4.1 INSTRUMENT BASED PRODUCTS 155
    • 10.4.2 PLATFORM BASED PRODUCTS 155
    • 10.4.3 KITS AND REAGENTS 155
    • 10.4.4 OTHER CONSUMABLES 156
  • 10.5 RESEARCH 156
    • 10.5.1 INSTRUMENT BASED PRODUCTS 157
    • 10.5.2 PLATFORM BASED PRODUCTS 157
    • 10.5.3 KITS AND REAGENTS 157
    • 10.5.4 OTHER CONSUMABLES 157

11 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE 158

  • 11.1 OVERVIEW 159
  • 11.2 STAGE IV 161
  • 11.3 STAGE I 162
  • 11.4 STAGE III 163
  • 11.5 STAGE II 164
  • 11.6 STAGE 0 165

12 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TECHNOLOGY 166

  • 12.1 OVERVIEW 167
  • 12.2 FLUORESCENT IN SITU HYBRIDIZATION 169
  • 12.3 NEXT GENERATION SEQUENCING 170
  • 12.4 FLUORIMMUNOASSAY 171
  • 12.5 COMPARATIVE GENOMIC HYBRIDIZATION 172
  • 12.6 IMMUNOHISTOLOCHEMICAL 172
  • 12.7 OTHER 173

13 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY PRODUCT 174

  • 13.1 OVERVIEW 175
  • 13.2 INSTRUMENT BASED PRODUCTS 177
    • 13.2.1 IMAGING 178
    • 13.2.2 BIOPSY 178
  • 13.3 PLATFORM BASED PRODUCTS 179
    • 13.3.1 NEXT-GENERATION SEQUENCING 180
    • 13.3.2 MICROARRAYS 180
    • 13.3.3 PCR 180
    • 13.3.4 OTHERS 180
  • 13.4 KITS AND REAGENTS 180
    • 13.4.1 NON-HODGKIN LYMPHOMA PANELS 181
    • 13.4.2 IMMUNOHISTOCHEMISTRY STAINS 181
    • 13.4.3 OTHERS 181
  • 13.5 OTHER CONSUMABLES 182

14 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY END USER 183

  • 14.1 OVERVIEW 184
  • 14.2 HOSPITALS 186
  • 14.3 DIAGNOSTIC CENTERS 187
  • 14.4 CANCER RESEARCH CENTERS 188
  • 14.5 ACADEMIC INSTITUTES 189
  • 14.6 AMBULATORY SURGICAL CENTERS 189
  • 14.7 OTHERS 190

15 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 191

  • 15.1 OVERVIEW 192
  • 15.2 DIRECT TENDER 194
  • 15.3 RETAIL SALES 195
  • 15.4 OTHERS 196

16 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION 197

  • 16.1 MIDDLE EAST AND AFRICA 198
    • 16.1.1 SOUTH AFRICA 216
    • 16.1.2 SAUDI ARABIA 229
    • 16.1.3 U.A.E. 242
    • 16.1.4 EGYPT 255
    • 16.1.5 ISRAEL 269
    • 16.1.6 REST OF MIDDLE EAST AND AFRICA 283

17 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 284

  • 17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 284

18 SWOT ANALYSIS 285

19 MIDDLE EAST & AFRICA NON-HODKIN LYMPHOMA DIAGNOSTICS MARKET 286

  • 19.1 CANON MEDICAL SYSTEMS CORPORATION 286
    • 19.1.1 COMPANY SNAPSHOT 286
    • 19.1.2 REVENUE ANALYSIS 286
    • 19.1.3 COMPANY SHARE ANALYSIS 287
    • 19.1.4 PRODUCT PORTFOLIO 287
    • 19.1.5 RECENT DEVELOPMENT 287
  • 19.2 KONINKLIJKE PHILIPS N.V. 288
    • 19.2.1 COMPANY SNAPSHOT 288
    • 19.2.2 REVENUE ANALYSIS 288
    • 19.2.3 COMPANY SHARE ANALYSIS 289
    • 19.2.4 PRODUCT PORTFOLIO 289
    • 19.2.5 RECENT DEVELOPMENTS 289
  • 19.3 SIEMENS HEALTHCARE GMBH 290
    • 19.3.1 COMPANY SNAPSHOT 290
    • 19.3.2 REVENUE ANALYSIS 290
    • 19.3.3 COMPANY SHARE ANALYSIS 291
    • 19.3.4 PRODUCT PORTFOLIO 291
    • 19.3.5 RECENT DEVELOPMENT 292
  • 19.4 DANAHER. 293
    • 19.4.1 COMPANY SNAPSHOT 293
    • 19.4.2 REVENUE ANALYSIS 293
    • 19.4.3 COMPANY SHARE ANALYSIS 294
    • 19.4.4 PRODUCT PORTFOLIO 294
    • 19.4.5 RECENT DEVELOPMENTS 295
  • 19.5 BIO-RAD LABORATORIES, INC. 296
    • 19.5.1 COMPANY SNAPSHOT 296
    • 19.5.2 REVENUE ANALYSIS 296
    • 19.5.3 COMPANY SHARE ANALYSIS 297
    • 19.5.4 PRODUCT PORTFOLIO 297
    • 19.5.5 RECENT DEVELOPMENT 297
  • 19.6 AGILENT TECHNOLOGIES, INC. 298
    • 19.6.1 COMPANY PROFILE 298
    • 19.6.2 REVENUE ANALYSIS 298
    • 19.6.3 PRODUCT PORTFOLIO 299
    • 19.6.4 RECENT DEVELOPMENT 299
  • 19.7 CENTOGENE N.V. 300
    • 19.7.1 COMPANY SNAPSHOT 300
    • 19.7.2 PRODUCT PORTFOLIO 300
    • 19.7.3 RECENT DEVELOPMENT 300
  • 19.8 F. HOFFMANN- LA ROCHE LTD 301
    • 19.8.1 COMPANY SNAPSHOT 301
    • 19.8.2 REVENUE ANALYSIS 301
    • 19.8.3 PRODUCT PORTFOLIO 302
    • 19.8.4 RECENT DEVELOPMENTS 302
  • 19.9 GENERAL ELECTRIC COMPANY 303
    • 19.9.1 COMPANY SNAPSHOT 303
    • 19.9.2 REVENUE ANALYSIS 303
    • 19.9.3 PRODUCT PORTFOLIO 304
    • 19.9.4 RECENT DEVELOPMENTS 304
Show more
  • 19.10 GENEDX, LLC 305
    • 19.10.1 COMPANY SNAPSHOT 305
    • 19.10.2 PRODUCT PORTFOLIO 305
    • 19.10.3 RECENT DEVELOPMENT 305
  • 19.11 GRAIL 306
    • 19.11.1 COMPANY PROFILE 306
    • 19.11.2 PRODUCT PORTFOLIO 306
    • 19.11.3 RECENT DEVELOPMENT 306

 

  • 19.12 HOLOGIC INC. 307
    • 19.12.1 COMPANY SNAPSHOT 307
    • 19.12.2 REVENUE ANALYSIS 307
    • 19.12.3 PRODUCT PORTFOLIO 308
    • 19.12.4 RECENT DEVELOPMENT 308
  • 19.13 INVITAE CORPORATION 309
    • 19.13.1 COMPANY PROFILE 309
    • 19.13.2 REVENUE ANALYSIS 309
    • 19.13.3 PRODUCT PORTFOLIO 310
    • 19.13.4 RECENT DEVELOPMENT 310
  • 19.14 NEUSOFT CORPORATION 311
    • 19.14.1 COMPANY SNAPSHOT 311
    • 19.14.2 REVENUE ANALYSIS 311
    • 19.14.3 PRODUCT PORTFOLIO 312
    • 19.14.4 RECENT DEVELOPMENT 312
  • 19.15 NEOGENOMICS LABORATORIES 313
    • 19.15.1 COMPANY SNAPSHOT 313
    • 19.15.2 REVENUE ANALYSIS 313
    • 19.15.3 PRODUCT PORTFOLIO 314
    • 19.15.4 RECENT DEVELOPMENTS 314
  • 19.16 PERKINELMER INC 315
    • 19.16.1 COMPANY PROFILE 315
    • 19.16.2 REVENUE ANALYSIS 315
    • 19.16.3 PRODUCT PORTFOLIO 316
    • 19.16.4 RECENT DEVELOPMENT 316
  • 19.17 QIAGEN 317
    • 19.17.1 COMPANY SNAPSHOT 317
    • 19.17.2 REVENUE ANALYSIS 317
    • 19.17.3 PRODUCT PORTFOLIO 318
    • 19.17.4 RECENT DEVELOPMENT 318
  • 19.18 SYSMEX CORPORATION 319
    • 19.18.1 COMPANY SNAPSHOT 319
    • 19.18.2 REVENUE ANALYSIS 319
    • 19.18.3 PRODUCT PORTFOLIO 320
    • 19.18.4 RECENT DEVELOPMENTS 320

20 QUESTIONNAIRE 321

21 RELATED REPORTS 325

LIST OF TABLES

  • TABLE 1 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 68
  • TABLE 2 MIDDLE EAST & AFRICA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 69
  • TABLE 3 MIDDLE EAST & AFRICA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 69
  • TABLE 4 MIDDLE EAST & AFRICA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 71
  • TABLE 5 MIDDLE EAST & AFRICA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 71
  • TABLE 6 MIDDLE EAST & AFRICA IMMUNOHISTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 72
  • TABLE 7 MIDDLE EAST & AFRICA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 73
  • TABLE 8 MIDDLE EAST & AFRICA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 73
  • TABLE 9 MIDDLE EAST & AFRICA GENETIC TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 74
  • TABLE 10 MIDDLE EAST & AFRICA CYTOGENETICS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
  • TABLE 11 MIDDLE EAST & AFRICA LUMBAR PUNCTURE (SPINAL TAP) IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
  • TABLE 12 MIDDLE EAST & AFRICA BLOOD TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 76
  • TABLE 13 MIDDLE EAST & AFRICA CYTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 77
  • TABLE 14 MIDDLE EAST & AFRICA OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 77
  • TABLE 15 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 81
  • TABLE 16 MIDDLE EAST & AFRICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
  • TABLE 17 MIDDLE EAST & AFRICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 82
  • TABLE 18 MIDDLE EAST & AFRICA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 83
  • TABLE 19 MIDDLE EAST & AFRICA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 84
  • TABLE 20 MIDDLE EAST & AFRICA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 85
  • TABLE 21 MIDDLE EAST & AFRICA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 86
  • TABLE 22 MIDDLE EAST & AFRICA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 87
  • TABLE 23 MIDDLE EAST & AFRICA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 88
  • TABLE 24 MIDDLE EAST & AFRICA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
  • TABLE 25 MIDDLE EAST & AFRICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 89
  • TABLE 26 MIDDLE EAST & AFRICA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 90
  • TABLE 27 MIDDLE EAST & AFRICA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 91
  • TABLE 28 MIDDLE EAST & AFRICA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 92
  • TABLE 29 MIDDLE EAST & AFRICA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 93
  • TABLE 30 MIDDLE EAST & AFRICA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 94
  • TABLE 31 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 98
  • TABLE 32 MIDDLE EAST & AFRICA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 99
  • TABLE 33 MIDDLE EAST & AFRICA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 99
  • TABLE 34 MIDDLE EAST & AFRICA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 100
  • TABLE 35 MIDDLE EAST & AFRICA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 101
  • TABLE 36 MIDDLE EAST & AFRICA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 102
  • TABLE 37 MIDDLE EAST & AFRICA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 102
  • TABLE 38 MIDDLE EAST & AFRICA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 103
  • TABLE 39 MIDDLE EAST & AFRICA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 104
  • TABLE 40 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 108
  • TABLE 41 MIDDLE EAST & AFRICA STAGE IV IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 109
  • TABLE 42 MIDDLE EAST & AFRICA STAGE I IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 110
  • TABLE 43 MIDDLE EAST & AFRICA STAGE III IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 111
  • TABLE 44 MIDDLE EAST & AFRICA STAGE II IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION 111
  • TABLE 45 MIDDLE EAST & AFRICA STAGE 0 IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 112
  • TABLE 46 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 116
  • TABLE 47 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 117
  • TABLE 48 MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 118
  • TABLE 49 MIDDLE EAST & AFRICA FLUORIMMUNOASSAY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 118
  • TABLE 50 MIDDLE EAST & AFRICA COMPARATIVE GENOMIC HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 119
  • TABLE 51 MIDDLE EAST & AFRICA IMMUNOHISTOCHEMICAL IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 120
  • TABLE 52 MIDDLE EAST & AFRICA OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 120
  • TABLE 53 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 124
  • TABLE 54 MIDDLE EAST & AFRICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 125
  • TABLE 55 MIDDLE EAST & AFRICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 125
  • TABLE 56 MIDDLE EAST & AFRICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 126
  • TABLE 57 MIDDLE EAST & AFRICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 127
  • TABLE 58 MIDDLE EAST & AFRICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 128
  • TABLE 59 MIDDLE EAST & AFRICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 128
  • TABLE 60 MIDDLE EAST & AFRICA OTHER CONSUMABLES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)) 129
  • TABLE 61 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 133
  • TABLE 62 MIDDLE EAST & AFRICA HOSPITALS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 134
  • TABLE 63 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 135
  • TABLE 64 MIDDLE EAST & AFRICA CANCER RESEARCH CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 135
  • TABLE 65 MIDDLE EAST & AFRICA ACADEMIC INSTITUTES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 136
  • TABLE 66 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 137
  • TABLE 67 MIDDLE EAST & AFRICA OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 137
  • TABLE 68 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 141
  • TABLE 69 MIDDLE EAST & AFRICA DIRECT TENDER IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 142
  • TABLE 70 MIDDLE EAST & AFRICA RETAIL SALES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 142
  • TABLE 71 MIDDLE EAST & AFRICA OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 143
  • TABLE 72 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 150
  • TABLE 73 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 150
  • TABLE 74 MIDDLE EAST AND AFRICA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 151
  • TABLE 75 MIDDLE EAST AND AFRICA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 151
  • TABLE 76 MIDDLE EAST AND AFRICA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 151
  • TABLE 77 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 152
  • TABLE 78 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 152
  • TABLE 79 MIDDLE EAST AND AFRICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 152
  • TABLE 80 MIDDLE EAST AND AFRICA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 153
  • TABLE 81 MIDDLE EAST AND AFRICA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 153
  • TABLE 82 MIDDLE EAST AND AFRICA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 153
  • TABLE 83 MIDDLE EAST AND AFRICA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 154
  • TABLE 84 MIDDLE EAST AND AFRICA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 154
  • TABLE 85 MIDDLE EAST AND AFRICA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 154
  • TABLE 86 MIDDLE EAST AND AFRICA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 87 MIDDLE EAST AND AFRICA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 155
  • TABLE 88 MIDDLE EAST AND AFRICA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 156
  • TABLE 89 MIDDLE EAST AND AFRICA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 156
  • TABLE 90 MIDDLE EAST AND AFRICA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 156
  • TABLE 91 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 157
  • TABLE 92 MIDDLE EAST AND AFRICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 157
  • TABLE 93 MIDDLE EAST AND AFRICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 157
  • TABLE 94 MIDDLE EAST AND AFRICA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 157
  • TABLE 95 MIDDLE EAST AND AFRICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 158
  • TABLE 96 MIDDLE EAST AND AFRICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 158
  • TABLE 97 MIDDLE EAST AND AFRICA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 158
  • TABLE 98 MIDDLE EAST AND AFRICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 159
  • TABLE 99 MIDDLE EAST AND AFRICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 159
  • TABLE 100 MIDDLE EAST AND AFRICA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 159
  • TABLE 101 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 160
  • TABLE 102 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 160
  • TABLE 103 MIDDLE EAST AND AFRICA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 161
  • TABLE 104 MIDDLE EAST AND AFRICA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 161
  • TABLE 105 MIDDLE EAST AND AFRICA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 161
  • TABLE 106 MIDDLE EAST AND AFRICA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 162
  • TABLE 107 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 162
  • TABLE 108 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 162
  • TABLE 109 SOUTH AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 110 SOUTH AFRICA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 111 SOUTH AFRICA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 112 SOUTH AFRICA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 113 SOUTH AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 165
  • TABLE 114 SOUTH AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 115 SOUTH AFRICA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 116 SOUTH AFRICA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 166
  • TABLE 117 SOUTH AFRICA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 166
  • TABLE 118 SOUTH AFRICA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 166
  • TABLE 119 SOUTH AFRICA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 167
  • TABLE 120 SOUTH AFRICA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 167
  • TABLE 121 SOUTH AFRICA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 167
  • TABLE 122 SOUTH AFRICA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 123 SOUTH AFRICA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 168
  • TABLE 124 SOUTH AFRICA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 168
  • TABLE 125 SOUTH AFRICA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 169
  • TABLE 126 SOUTH AFRICA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 169
  • TABLE 127 SOUTH AFRICA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 169

LIST OF FIGURES

  • FIGURE 1 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION 35
  • FIGURE 2 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DATA TRIANGULATION 38
  • FIGURE 3 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DROC ANALYSIS 39
  • FIGURE 4 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 40
  • FIGURE 5 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 40
  • FIGURE 6 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MULTIVARIATE MODELLING 41
  • FIGURE 7 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 42
  • FIGURE 8 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 43
  • FIGURE 9 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID 44
  • FIGURE 10 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 45
  • FIGURE 11 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION 49
  • FIGURE 12 THE INCREASING PREVALENCE OF NON-HODGKIN LYMPHOMA AND INCREASED RESEARCH & DEVELOPMENT IN NON-HODGKIN LYMPHOMA DIAGNOSTICS ARE DRIVING THE MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 50
  • FIGURE 13 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN 2021 & 2028 50
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET 57
  • FIGURE 15 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2022 65
  • FIGURE 16 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 66
  • FIGURE 17 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030) 66
  • FIGURE 18 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE 67
  • FIGURE 19 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2022 78
  • FIGURE 20 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2023-2030 (USD MILLION) 79
  • FIGURE 21 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, CAGR (2023-2030) 79
  • FIGURE 22 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, LIFELINE CURVE 80
  • FIGURE 23 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2022 95
  • FIGURE 24 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 96
  • FIGURE 25 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2023-2030) 96
  • FIGURE 26 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE 97
  • FIGURE 27 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2022 105
  • FIGURE 28 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION) 106
  • FIGURE 29 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030) 106
  • FIGURE 30 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE 107
  • FIGURE 31 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2022 113
  • FIGURE 32 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 114
  • FIGURE 33 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, CAGR (2023-2030) 114
  • FIGURE 34 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, LIFELINE CURVE 115
  • FIGURE 35 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2022 121
  • FIGURE 36 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2023-2030 (USD MILLION) 122
  • FIGURE 37 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, CAGR (2023-2030) 122
  • FIGURE 38 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, LIFELINE CURVE 123
  • FIGURE 39 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2022 130
  • FIGURE 40 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION) 131
  • FIGURE 41 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030) 131
  • FIGURE 42 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE 132
  • FIGURE 43 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2022 138
  • FIGURE 44 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 139
  • FIGURE 45 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 139
  • FIGURE 46 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 140
  • FIGURE 47 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SNAPSHOT (2022) 145
  • FIGURE 48 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022) 147
  • FIGURE 49 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 147
  • FIGURE 50 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 148
  • FIGURE 51 MIDDLE EAST AND AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 148
  • FIGURE 52 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 230
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!